Safety of formoterol by Turbuhaler® as reliever medication compared with terbutaline in moderate asthma

The present study compared the safety of 4.5 µg formoterol with 0.5 mg terbutaline, both by Turbuhaler® and used as needed, in addition to regular formoterol in moderate asthma. In this double-blind parallel-group study, 357 patients taking a moderate-to-high dose of inhaled corticosteroids and additional terbutaline (2–5 inhalations·day−1 during run-in) were randomised to either formoterol or terbutaline as needed in addition to formoterol 9 µg b.i.d. over 12 weeks. Adverse events, serum potassium levels, electrocardiogram, vital signs and lung function were assessed monthly; peak expiratory flow and severe asthma exacerbations were recorded daily. Patients used 2.16 (range 0.0–6.3) formoterol and 2.34 (range 0.1–7.5) terbutaline relief inhalations·day−1. No clinically significant differences in safety variables were found between treatments. Statistically greater increases in cardiac frequency (2.6 beats·min−1, p=0.03) were found on terbutaline. There were 44 and 52 severe asthma exacerbations with formoterol and terbutaline, respectively, with no significant difference in time to first exacerbation. There was also no difference between treatments for other efficacy measures (peak expiratory flow, forced expiratory volume in one second and morning/evening symptom scores). Formoterol 4.5 µg as needed was at least as safe, well tolerated and effective as terbutaline 0.5 mg in stable patients (requiring up to 6 relief inhalations·day−1) taking formoterol plus inhaled corticosteroids regularly over 12 weeks.

[1]  A Tattersfield,et al.  Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. , 2001, American journal of respiratory and critical care medicine.

[2]  D. Postma,et al.  Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial , 2001, The Lancet.

[3]  B. Psaty,et al.  Risk of myocardial ischaemia and beta-adrenoceptor agonists , 2001, Annals of medicine.

[4]  A. von Berg,et al.  Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. , 2000, Respiratory medicine.

[5]  A. Andersson,et al.  Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. , 2000, Respiratory medicine.

[6]  B. Psaty,et al.  The Risk of Myocardial Infarction Associated with Inhaled β -Adrenoceptor Agonists , 2000 .

[7]  R. Aalbers,et al.  Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. , 1999, The European respiratory journal.

[8]  O. Selroos,et al.  Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. , 1998, The European respiratory journal.

[9]  T. Ekström,et al.  A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[10]  T. Ekström,et al.  Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). , 1998, Respiratory medicine.

[11]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[12]  J. Malo,et al.  Effects of the long acting b agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids , 1998 .

[13]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[14]  J. Lötvall,et al.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[15]  D. Postma,et al.  Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. , 1997, Thorax.

[16]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[17]  A. Schreurs,et al.  A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. , 1996, The European respiratory journal.

[18]  R. Fuller,et al.  Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma? , 1995, Chest.

[19]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[20]  M. Sears,et al.  The β2-Agonist Controversy , 1994 .

[21]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[22]  M. Sears,et al.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. , 1994, Drug safety.

[23]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[24]  J. Palmer,et al.  Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease — a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 μg) with salmeterol (50 μg) , 1992 .

[25]  G. Persson,et al.  Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects. , 1992, Chest.

[26]  S. Larsson,et al.  Inhaled formoterol during one year in asthma: a comparison with salbutamol. , 1991, The European respiratory journal.

[27]  P. O'Byrne,et al.  Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. , 1991, The American review of respiratory disease.

[28]  I. Pavord,et al.  Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma , 1990, The Lancet.

[29]  T. Sandström,et al.  Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. , 1990, Thorax.

[30]  S. Larsson,et al.  Formoterol, a new long-acting bronchodilator for inhalation. , 1989, The European respiratory journal.

[31]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[32]  A. Miller,et al.  Standardized lung function testing. , 1984, Bulletin europeen de physiopathologie respiratoire.